Halozyme (HALO) AI Stock Analysis

0 Followers

Halozyme

(BMV:HALO)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Royalty Portfolio GrowthBroad-based royalty growth across multiple commercial products demonstrates that Halozyme is benefiting from expanding adoption of ENHANZE-enabled therapies. Diversification across partners and indications supports recurring revenue durability and reduces reliance on any single product over the next several quarters.

Negative Factors

High Leverage and Negative EquityElevated debt alongside negative shareholder equity reduces financial flexibility and makes the capital structure more sensitive to any weakening in operating performance. Although cash generation is strong, substantial leverage can constrain investment choices and increase refinancing or repayment pressure.

Halozyme (HALO) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 11.69B
Dividend Yield: ―
Average Volume (3M): 484
Price to Earnings (P/E): 24.5
Beta (1Y): 0.37
Revenue Growth: 30.42%
EPS Growth: -24.96%
Country: Mexico
Employees: 423
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Halozyme Business Overview & Revenue Model

Company Description

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHAN...

Halozyme Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-17.72%|Next Earnings Date:Feb 23, 2027

Earnings Call SentimentPositive

The call was strongly positive, supported by record revenue and royalty results, raised 2026 guidance, broad-based commercial product growth, expanding partner agreements, pipeline advancement and progress with Hypercon and Aerocon. The main negative items were higher operating expenses, adverse initial U.S. patent rulings, ongoing litigation and development and collaboration-revenue timing uncertainties, but these were outweighed by the reported operating momentum and growth opportunities.

Positive Updates

Record Third-Quarter Revenue and Profitability

Total revenue increased 39% year-over-year to $493 million, royalty revenue increased 44% to a record $341 million, adjusted EBITDA increased 35% to $336.2 million, and adjusted EBITDA margin was 68%. Net income increased 41% to $247 million, GAAP diluted EPS increased to $2.01 from $1.43, and non-GAAP diluted EPS increased to $2.39 from $1.72.

Negative Updates

Higher Research and Development Expenses

Research and development expenses increased to $27.8 million from $17.3 million in the prior-year period, reflecting continued investment in advancing ENHANZE and next-generation technology platforms.

Company Guidance

Halozyme raised 2026 guidance to total revenue of $1.86 billion to $1.925 billion, representing growth of 33% to 38% over 2025; royalty revenue of $1.235 billion to $1.255 billion, representing growth of 42% to 45%; product sales of $525 million to $540 million; adjusted EBITDA of $1.24 billion to $1.29 billion, with adjusted EBITDA margin unchanged at approximately 67%; and non-GAAP diluted EPS of $8.75 to $9.05. The company expects 13 ENHANZE programs in clinical development by year-end 2026, Hypercon’s first clinical trial start in the first half of 2027, Aerocon new deal signings in 2027 and clinical entry in the second half of 2028, and up to 13 new products to launch between '29 and 2032, with development timelines of 4.5 to 5.5 years; it plans to provide 2027 guidance and an update on its long-range outlook when it reports fourth quarter results in February.

Halozyme Risk Analysis

Halozyme disclosed 40 risk factors in its most recent earnings report. Halozyme reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Halozyme Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:HALO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASND	68Neutral	$16.01B	18.99	190.44%	―	128.41%	―
LGND	68Neutral	$6.28B	121.30	5.22%	―	1.03%	8.35%
XERS	66Neutral	$2.89B	-394.76	-39.52%	―	38.37%	63.43%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ARWR	49Neutral	$6.92B	-21.88	-60.54%	―	16.85%	-80.39%
IONS	42Neutral	$4.69B	-8.49	-120.41%	―	-0.79%	-106.48%

* Healthcare Sector Average

Performance Comparison

MX:HALO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:HALO	Halozyme Therapeutics	1950.00	674.99	52.94%
ARWR	Arrowhead Pharmaceuticals, Inc.	49.00	7.86	19.11%
IONS	Ionis Pharmaceuticals Inc.	28.19	-41.65	-59.64%
LGND	Ligand Pharmaceuticals Inc	314.16	112.89	56.09%
ASND	Ascendis Pharma A/S	256.59	50.14	24.29%
XERS	Xeris Pharmaceuticals	15.83	8.57	118.04%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Halozyme AI Stock Analysis